← All trials
NCT05086107
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 8, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Apr 30, 2022
- First posted
- Oct 20, 2021
- Last posted
- Oct 20, 2021
- Enrollment
- 48
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BioVersys SASLead sponsor
- CRU Hungary Early Phase UnitCollaborator
- CRU Hungary Early Phase UnitCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.